Journal: PLOS One

Article Title: RIPK2 induces docetaxel resistance in prostate cancer through the NF-κB/P-gp signaling pathway

doi: 10.1371/journal.pone.0341445

Figure Lengend Snippet: (A) 22RV1/DTX, C4-2/DTX, PC-3/DTX, and DU145/DTX cells were treated with DTX (0.001 ~ 100 nM) for 48 h. Cell viability was measured by CCK-8 assay. (B) Western blotting was performed to detect the expression level of RIPK2 in normal and drug-resistant prostate cancer cells. (C) Effect of DTX on 22RV1/DTX, C4-2/DTX, PC-3/DTX, and DU145/DTX cell viability after siRNA interference with RIPK2 expression. (D) Crystalline violet staining assay to detect the sensitivity of PC-3/DTX cells to DTX after RIPK2 silencing. (E) RIPK2 protein expression level in PC-3 cells after transfection with RIPK2 plasmid. RIPK2 expression levels in PC-3 cells after transfection with the RIPK2 plasmid. Sensitivity of PC-3 cells to DTX was detected by CCK-8 assay (F) and crystal violet staining (G) after overexpression of RIPK2. ** P < 0.01. n = 3 in A-G.

Article Snippet: The Cell Counting Kit-8 (CCK-8, MedChem Express) assay was performed as follows: cells were inoculated in 96-well plates overnight and treated with a DTX concentration gradient (0.001–100 nM) for 48 h. Ten microliters of CCK-8 solution were added to each well according to the manufacturer’s instructions and incubated for 4 h. Absorbance was measured at 450 nm using an enzyme marker (Bio-Rad, Hercules, CA, USA).

Techniques: CCK-8 Assay, Western Blot, Expressing, Staining, Transfection, Plasmid Preparation, Over Expression